Treatment of Diffuse Alveolar Hemorrhage (DAH)
Initial Management and Diagnosis
- The American College of Rheumatology recommends establishing the diagnosis through bronchoalveolar lavage showing increasingly bloody returns in sequential aliquots 1
- Begin empiric immunosuppressive therapy immediately when immune-mediated DAH is suspected, as delayed treatment dramatically worsens outcomes 1
Glucocorticoid Dosing Protocol
- The European League Against Rheumatism (EULAR) guidelines suggest administering intravenous methylprednisolone 500-1000 mg/day for 3 consecutive days (maximum cumulative dose of 3 grams) for severe DAH with hypoxemia 1
- Transition to weight-based oral prednisone:
Immunosuppressive Therapy Selection
- Choose rituximab over cyclophosphamide as the preferred agent when combined with glucocorticoids for remission induction 1
- Continue maintenance immunosuppression for 18 months to 4 years after remission to prevent relapse in ANCA-associated vasculitis 1
Plasma Exchange Considerations
- Consider plasma exchange for DAH with hypoxemia, particularly when serum creatinine >300 μmol/L (>3.4 mg/dL), requiring dialysis, or with concomitant anti-GBM disease 1
- The 2024 EULAR guidelines reveal that no clinically relevant benefit of plasma exchange was demonstrated for DAH mortality in the PEXIVAS trial (191 patients with DAH, 61 with hypoxemia) 3, 2, 4
Ventilator Management for Severe Cases
- Use lung-protective ventilation strategies with tidal volumes: 6-8 mL/kg predicted body weight 1
- Plateau pressure: ≤30 cmH₂O 3
Critical Contraindications in DAH
- Do not perform chest physiotherapy maneuvers including manual hyperinflation, postural drainage with head-down positioning, percussion, vibratory shaking, or forced expiration techniques, as these can precipitate hemodynamic collapse and extend capillary damage 1
Etiology-Specific Considerations
- DAH occurs in approximately 25% of ANCA-associated vasculitis patients 1
- Mortality risk factors include older age, severe kidney failure, degree of hypoxemia, and >50% lung area involvement 1
Adjunctive Therapies
- Avacopan may be considered as adjunctive therapy to reduce glucocorticoid exposure in patients at high risk for steroid toxicity 1
Monitoring Parameters
- Track oxygenation parameters (PaO₂/FiO₂ ratio improvement) to assess treatment response 1
- Chest imaging for resolution of ground-glass opacities and consolidation 5
Infectious DAH
- If infectious etiology is suspected, initiate broad-spectrum antibiotics with β-lactam plus macrolide or respiratory fluoroquinolone, with MRSA coverage in high-risk patients 5
Refractory Disease Management
- For patients not responding to standard therapy, refer immediately to a center with expertise in vasculitis 3, 2, 4, 1